All Stories

  1. Darolutamide For Castration-Resistant Prostate Cancer

    Article • OncoTargets and Therapy, October 2019, Taylor & Francis

    Catherine Handy

  2. Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data

    Article • Journal of Medical Economics, August 2019, Taylor & Francis

    Catherine Handy

  3. Clinical implications of mismatch repair deficiency in prostate cancer

    Article • Future Oncology, June 2019, Future Medicine

    Catherine Handy

  4. Sipuleucel-T treatment in prostate cancer

    Article • Future Oncology, December 2017, Future Medicine

    Catherine Handy

  5. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications

    Article • Therapeutic Advances in Medical Oncology, July 2017, SAGE Publications

    Catherine Handy

  6. Treatment strategies for DNA repair-deficient prostate cancer

    Article • Expert Review of Clinical Pharmacology, June 2017, Taylor & Francis

    Catherine Handy

  7. Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis

    Article • Prostate Cancer, January 2017, Hindawi Publishing Corporation

    Catherine Handy

  8. Galeterone for the treatment of advanced prostate cancer: the evidence to date

    Article • Drug Design Development and Therapy, July 2016, Dove Medical Press

    Catherine Handy

  9. Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer

    Article • Clinical Medicine Insights Oncology, January 2016, SAGE Publications

    Catherine Handy

  10. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?

    Article • Expert Review of Anticancer Therapy, December 2014, Taylor & Francis

    Catherine Handy

  11. Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer

    Article • The Prostate, August 2014, Wiley

    Catherine Handy

  12. Castration-resistant prostate cancer: latest evidence and therapeutic implications

    Article • Therapeutic Advances in Medical Oncology, April 2014, SAGE Publications

    Catherine Handy

  13. Association of pretreatment neutrophil‐to‐lymphocyte ratio ( NLR ) and overall survival ( OS ) in patients with metastatic castration‐resistant prosta...

    Article • BJU International, February 2014, Wiley

    Catherine Handy

  14. Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all

    Article • Asian Journal of Andrology, January 2014, Medknow

    Catherine Handy

  15. Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer

    Article • Core Evidence, April 2013, Taylor & Francis

    Catherine Handy

  16. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer

    Article • Drug Design Development and Therapy, March 2011, Taylor & Francis

    Catherine Handy

  17. Corrigendum

    Article • Drug Design Development and Therapy, March 2011, Taylor & Francis

    Catherine Handy